Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 26, Issue 10, 2007, Pages 1019-1024

  Kijpittayarit Arthurs, Supha ^a   Eid, Albert J ^a   Kremers, Walter K ^a   Pedersen, Rachel A ^a   Dierkhising, Ross A ^a   Patel, Robin ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; MALE; MORTALITY; PRIORITY JOURNAL; RECIPIENT; RESTRICTIVE CARDIOMYOPATHY; RISK FACTOR; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34848820267     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.07.016     Document Type: Article

References (32)

1. Paya C.V., and Razonable R.R. Cytomegalovirus infection after solid organ transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed (2003), Lippincott Williams and Wilkins, Philadelphia 298-325
2. Petrakopoulou P., Kubrich M., Pehlivanli S., et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 110 (2004) II-207-II-212
3. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transplant Infect Dis 3 suppl 2 (2001) 44-48
4. Egan J.J., Carroll K.B., Yonan N., Woodcock A., and Crisp A. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 21 (2002) 460-466
5. Antretter H., Hofer D., Hangler H., et al. Is it possible to reduce CMV infections after heart transplantation with a three-month antiviral prophylaxis?. 7 year experience with ganciclovir. Wien Klin Wochenschr 116 (2004) 542-551 [in German]
6. Vrtovec B., Thomas C.D., Radovancevic R., Frazier O.H., and Radovancevic B. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant 23 (2004) 461-465
7. Antretter H., Hofer D., Klaus A., Larcher C., Margreiter J., and Margreiter R. Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention [in German]. Dtsch Med Wochenschr 125 (2000) 445-451
8. Devyatko E., Zuckermann A., Ruzicka M., et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 23 (2004) 1277-1282
9. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 65 (1998) 747-752
10. Kunzle N., Petignat C., Francioli P., et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transplant Infect Dis 2 (2000) 118-126
11. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62 suppl (2005) S7-S13
12. Cytomegalovirus. Am J Transplant 4 suppl 10 (2004) 51-58
13. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
14. Radovancevic B., Konuralp C., Vrtovec B., et al. Factors predicting 10-year survival after heart transplantation. J Heart Lung Transplant 24 (2005) 156-159
15. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81 (2006) 1645-1652
16. Razonable R.R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184 (2001) 1461-1464
17. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
18. Razonable R.R., Brown R.A., Espy M.J., et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 39 (2001) 4472-4476
19. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
20. Steel H.M., and Murday A.J. Cytomegalovirus as a cause of morbidity in heart transplantation. The experience of one center. Transplantation 62 (1996) 492-496
21. Grossi P., Revello M.G., Minoli L., et al. Three-year experience with human cytomegalovirus infections in heart transplant recipients. J Heart Transplant 9 (1990) 712-719
22. Grossi P., De Maria R., Caroli A., Zaina M.S., and Minoli L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. J Heart Lung Transplant 11 (1992) 847-866
23. Kijpittayarit S., Deziel P., Eid A.J., and Razonable R.R. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 81 (2006) 137-138
24. Kijpittayarit S., Dierkhising R., and Colby C. Age and gender as predictors of delayed onset primary action (CMV) disease after liver transplantation. Abstract presentation at the American Transplant Congress (2007)
25. Razonable R.R., and Emery V.C. Management of CMV infection and disease in transplant patients. Herpes 11 (2004) 77-86
26. Turgeon N., Fishman J.A., Doran M., et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transplant Infect Dis 2 (2000) 2-10
27. Arabia F.A., Rosado L.J., Huston C.L., Sethi G.K., and Copeland III J.G. Incidence and recurrence of gastrointestinal cytomegalovirus infection in heart transplantation. Ann Thorac Surg 55 (1993) 8-11
28. Selinsky C., Luke C., Wloch M., et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 1 (2005) 16-23
29. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 suppl (2004) S187-S193
30. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 (2004) 169-177
31. Lemstrom K., Tikkanen J., Koskinen P., and Hayry P. Effect of cytomegalovirus on cardiac allograft arteriosclerosis-indirect or direct?. Am J Transplant 5 (2005) 421-422
32. Lemstrom K., Sihvola R., Bruggeman C., Hayry P., and Koskinen P. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 95 (1997) 2614-2616